Moffitt at SITC

Moffitt Experts Share Discoveries Driving Innovation in Cancer Immunotherapy

The Society for Immunotherapy of Cancer brings together industry leaders to highlight new research and clinical applications in immunotherapy

New Immunotherapy Combination Shows Promise in Advanced Lung Cancer

Adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients

AI Helps Predict Treatment Response in Melanoma

Identifying and analyzing immune cells under the microscope can help personalize therapies

TIL Therapy for Advanced Melanoma Offers Promising Results

The study shows 36% of patients experienced a positive response to the therapy

New Combination Therapy Brings Hope to Bladder Cancer Patients

Oncolytic immunotherapy and immune checkpoint inhibitor found to be safe and effective in treating muscle-invasive bladder cancer

A Novel Class of Therapeutic Biologics Shows Promise for HPV-Related Head and Neck Cancer

Combining two treatments may improve outcomes for patients with HPV 16–positive disease

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.

New Cancer Vaccine May Boost Immunotherapy in Treating Lung Cancer

Phase 2 trial results suggest IO102-IO103 combined with pembrolizumab may enhance response rates in advanced lung cancer

New Immunotherapy Strategy Shows Promise in Lung Cancer Treatment

Moffitt researchers advance a novel approach to boost the immune system’s ability to target lung cancer cells

Newly Approved Cell Therapy Afami-Cel Shows Long-Term Tumor Control in Synovial Sarcoma

Phase 2 clinical trial data suggests the engineered T cells can stay active in the body for more than three years